Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 51.1% in November

Talphera, Inc. (NASDAQ:TLPH) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 41,900 shares, a drop of 51.1% from the November 15th total of 85,600 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 99,700 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TLPH. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Friday, August 16th. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research note on Friday, November 8th.

Talphera Stock Down 1.1 %

Shares of TLPH traded down $0.01 during mid-day trading on Friday, hitting $0.65. 62,975 shares of the company’s stock were exchanged, compared to its average volume of 91,149. Talphera has a 52 week low of $0.62 and a 52 week high of $1.61. The stock’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $0.89. The firm has a market cap of $11.07 million, a price-to-earnings ratio of -0.94 and a beta of 0.25.

Hedge Funds Weigh In On Talphera

A number of hedge funds have recently added to or reduced their stakes in TLPH. Nantahala Capital Management LLC bought a new stake in shares of Talphera during the 2nd quarter valued at $1,773,000. Turtle Creek Wealth Advisors LLC acquired a new position in Talphera in the second quarter valued at about $64,000. Finally, Rosalind Advisors Inc. acquired a new position in Talphera in the third quarter valued at about $650,000. Institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.